Skip to main content
OpenTrials
Completed

NCT Number: NCT06891547

Radicle Spark for Women™ 24: Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

A randomized, double-blind, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on sexual health and related health outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sexual Satisfaction Behavior Orgasm Sexual Behavior Sexual Function

Age range

21 year–105 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Radicle Science, Inc

Del Mar, California, 92014, United States

About this study

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for improved libido (sex drive), sexual satisfaction and/or function, (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth is female
  • Resides in the United States
  • Endorses improved libido (sex drive), sexual satisfaction and/or function as a primary desire
  • Has the opportunity for at least 30% improvement in their primary health outcome
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion criteria

  • Report being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • Reports current enrollment in another clinical trial
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
  • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.

o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure

  • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.

o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products

  • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
  • Lack of reliable daily access to the internet

Treatment and study plan

Spark Placebo Control 5.1

Dietary Supplement

Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks.

Spark Active Study Product 5.1 Usage

Dietary Supplement

Participants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks.

Primary outcomes

  1. Change in sexual health

    Time frame: 6 weeks

    Mean difference in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Full Profile Sexual Function and Satisfaction Survey (Female) (where lower scores correspond to lower sexual function and satisfaction)

Secondary outcomes

  1. Change in feelings of stress

    Time frame: 6 weeks

    Mean difference in feelings of stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)

  2. Change in fatigue

    Time frame: 6 weeks

    Mean difference in fatigue as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)

  3. Change in mood (emotional distress-depression)

    Time frame: 6 weeks

    Mean difference in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; where higher scores correspond to more severe emotional distress-depression)

  4. Minimal clinical importance difference (MCID) in sexual health

    Time frame: 6 weeks

    Likelihood of achieving a MCID in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Full Profile Sexual Function and Satisfaction Survey (Female) (where lower scores correspond to lower sexual function and satisfaction)

  5. Minimal clinical importance difference (MCID) in feelings of stress

    Time frame: 6 weeks

    Likelihood of achieving a MCID in feelings of stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)

  6. Minimal clinical importance difference (MCID) in fatigue

    Time frame: 6 weeks

    Likelihood of achieving a MCID in feelings of fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)

  7. Minimal clinical importance difference (MCID) in mood (emotional distress-depression)

    Time frame: 6 weeks

    Likelihood of achieving a MCID in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; where higher scores correspond to more severe emotional distress-depression)

Other outcomes

  1. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (1)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based IgG (Immunoglobulin) biomarker (Optional; among consented participants only).

  2. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (2)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based cytokines (Interleukin 1 beta, Interleukin 8, Tumor necrosis factor-alpha, and Interleukin 6) biomarker. (Optional; among consented participants only).

  3. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (3)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based dehydroepiandrosterone sulfate (DHEA-S) biomarker. (Optional; among consented participants only).

  4. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (4)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based estradiol biomarker. (Optional; among consented participants only).

  5. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (5)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based progesterone biomarker. (Optional; among consented participants only).

  6. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (6)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based testosterone biomarker. (Optional; among consented participants only).

  7. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (7)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based cortisol biomarker. (Optional; among consented participants only).

  8. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (8)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based melatonin biomarker. (Optional; among consented participants only).

  9. Change in saliva concentration of at-home (direct-to-consumer) specimen assay (9)

    Time frame: 6 weeks

    Mean difference in saliva concentration as assessed by saliva-based C-Reactive Protein (CRP) biomarker. (Optional; among consented participants only).

  10. Change in blood concentration of at-home (direct-to-consumer) specimen assay (1)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based cortisol biomarker (1 drop). (Optional; among consented participants only).

  11. Change in blood concentration of at-home (direct-to-consumer) specimen assay (2)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based homocysteine biomarker (1 drop). (Optional; among consented participants only).

  12. Change in blood concentration of at-home (direct-to-consumer) specimen assay (3)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based ferritin biomarker (1 drop). (Optional; among consented participants only).

  13. Change in blood concentration of at-home (direct-to-consumer) specimen assay (4)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based thyroid stimulating hormone (TSH) biomarker (1 drop). (Optional; among consented participants only).

  14. Change in blood concentration of at-home (direct-to-consumer) specimen assay (5)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based hemoglobin A1C (HbA1c) biomarker (1 drop). (Optional; among consented participants only).

  15. Change in blood concentration of at-home (direct-to-consumer) specimen assay (6)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based insulin biomarker (1 drop). (Optional; among consented participants only).

  16. Change in blood concentration of at-home (direct-to-consumer) specimen assay (7)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based vitamin D biomarker (1 drop). (Optional; among consented participants only).

  17. Change in blood concentration of at-home (direct-to-consumer) specimen assay (8)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based dehydroepiandrosterone sulfate (DHEA-S) biomarker (1 drop). (Optional; among consented participants only).

  18. Change in blood concentration of at-home (direct-to-consumer) specimen assay (9)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based testosterone biomarker (1 drop) (Optional; among consented participants only).

  19. Change in blood concentration of at-home (direct-to-consumer) specimen assay (10)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based estradiol biomarker (1 drop). (Optional; among consented participants only).

  20. Change in blood concentration of at-home (direct-to-consumer) specimen assay (11)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based total cholesterol (high-density lipoproteins (HDL) and low-density lipoproteins (LDL)) biomarker (1 drop). (Optional; among consented participants only).

  21. Change in blood concentration of at-home (direct-to-consumer) specimen assay (12)

    Time frame: 6 weeks

    Mean difference in blood concentration as assessed by blood-based triglycerides (apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB)) (1 drop). (Optional; among consented participants only).

  22. Change in stool concentration of at-home (direct-to-consumer) specimen assay

    Time frame: 6 weeks

    Mean difference in stool concentration as assessed by a stool sample (microbial diversity) (Optional; among consented participants only).

Sponsors and collaborators

Lead sponsor

Radicle Science

Industry

Registry information

Official study title

Radicle Spark for Women™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 24, 2025
Registry last updated
Aug 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.